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Abstract
Although long regarded as the gold standard for liver fibrosis staging in chronic hepatitis C (CHC), liver biopsy (LB) implies both
the risk of an invasive procedure and significant variability. The aim of this study was to evaluate the diagnostic performance for
transient elastography (TE) and aspartate aminotransferase to platelet index (APRI) used alone and in combination compared
to liver biopsy and to analyze false positive/negative results. Patients with CHC, and no previous clinical diagnosis of cirrhosis
were enrolled to undergo liver biopsy, TE and APRI. A total of 182 adult patients with a median age of 55 years and median body
mass index of 26.71 kg/m2 were analyzed. On LB, 56% of patients had significant levels of fibrosis (METAVIR FX2) and 28%
had advanced fibrosis (F3/F4). The strongest performance for both tests was observed for exclusion of advanced fibrosis with
good negative predictive values (89 and 86%, respectively). Low necroinflammatory activity on LB was associated with false
negative TE. False positives were associated with NASH and smaller LB fragments. Correlation between APRI and Fibroscan
for FX2 was 100% and 84% for FX3 and remained high in both false negative and false positive instances, correctly identifying
Fo2 in 71% of cases and Fo3 in 78% (and potentially foregoing up to 84% of LB). We concluded that low individual
performance indicators could be attributable to limitations of LB. Poorer differentiation of lower levels of fibrosis is a known issue
for LB and remains so for noninvasive tests. Good predictability is possible, however, for advanced fibrosis.
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Introduction
Liver fibrosis (LF) staging is an important component
of chronic hepatitis C (CHC) management. While patients
exhibiting minimal or absent fibrosis progress slowly over
a long period of time, those with advanced fibrosis (septal
bridging or regenerative nodules) will almost invariably
progress to clinical cirrhosis in less than 10 years. Further-
more, LF is a major prognostic factor in CHC, directly
correlating to the risk of developing liver-related complica-
tions and death (1,2).
Although long regarded as the gold standard for
fibrosis staging, liver biopsy (LB) has limitations both in
diagnostic performance (either because of sampling error
or observer variability) (3) and regarding safety concerns,
with 0.3 to 0.6% overall risk for complications and a 0.05%
mortality rate (4). Notwithstanding, biopsy holds to this day
a paramount role in the diagnosis and management of
liver disease, as it can offer invaluable information regard-
ing inflammatory activity, steatosis, steatohepatitis, and
coexisting morbid conditions such as iron overload, auto
immune hepatitis features, among others.
In an attempt to overcome potential risks and expand
access and eligibility in LF staging, several noninvasive
approaches have been developed (5–8), some relying on
analysis of physical changes associated with liver fibrosis,
such as elastography, and others on biochemical markers
and scoring systems ranging from isolated platelet counts (9)
to more elaborate indexes, such as Fibrotest
s
, Fibro-
meter
s
, and Hepascore
s
. These indexes have variable
diagnostic performances (10–12), usually with stronger
predictability for advanced fibrosis and cirrhosis when
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compared to significant fibrosis or specific METAVIR level
staging.
Aspartate aminotransferase (AST) to platelet ratio
index (APRI) is one of the most validated and simple-
to-use scoring systems for fibrosis prediction and has
been reported to achieve areas under the receiver
operating curves (AUROCs) for the diagnosis of signifi-
cant fibrosis, advanced fibrosis and cirrhosis of 0.77, 0.80
and 0.83, respectively (13). However, those levels of
predictability are conditioned to optimal thresholds that
occur in less than 30% of patients (14).
Imaging techniques have also been developed such
as elastography, which measures liver stiffness (LS) and
correlates with liver fibrosis. Transient hepatic elastogra-
phy (TE) (Fibroscan
s
, Echosense, France) uses mechanic
shear wave velocity measurements through monodimen-
sional ultrasound (15), with 0.79, 0.91 and 0.97 AUROCs
for significant fibrosis, advanced fibrosis and cirrhosis,
respectively (16). However, previous reports have estab-
lished limited resolution in lower levels of fibrosis and in
patients with larger abdominal circumferences. Other
limitations of Fibroscan include ascites and physiological
or pathological processes associated with liver conges-
tion. Also, cost considerations still make elastography
inaccessible to many resource-limited areas.
Several attempts have been made to improve diagnostic
performances and likelihood ratios by combining different
tests and possibly overcoming their individual limitations.
Associating test modalities in a sequential or synchronous
approach can provide up to 85–90% predictability for
significant fibrosis or advanced fibrosis/cirrhosis (17–19).
Both elastography and biochemical scores present
promising noninvasive approaches for complementing
or even substituting histological analysis. Overall diag-
nostic performance across different patient populations,
however, remains questionable. Moreover, correlation
between TE and APRI, and potential uses for combined
diagnosis in clinical practice remain unclear. The aim of
this study was to evaluate diagnostic performances of
APRI and TE, alone and in combination, in a Brazilian
CHC population to detect significant fibrosis (FX2) or
advanced fibrosis (FX3) and to determine if LB could
potentially be avoided in a proportion of cases.
Material and Methods
Patient enrollment and data collection
For this prospective cross-sectional study, adult patients
(418 years) with CHC, followed in an outpatient university
hospital clinical setting (Ambulatório de Hepatites Virais of
the Universidade Estadual de Campinas) from January
2013 to June 2015, were included. CHC was defined as
positive detection of hepatitis C virus (HCV) RNA (Abbot
Real Time HCV Abbott Laboratories, Germany) in serum
samples obtained at least 6 months after initial seroposi-
tivity for antibodies against HCV.
Exclusion criteria were co-infection with human immuno-
deficiency virus (HIV) or hepatitis B virus (HBV), decom-
pensated liver disease (presence or history of ascites),
hepatic encephalopathy, portal hypertension-related bleeding
or hepatocellular carcinoma (HCC), prior liver transplanta-
tion or patients with clinical, radiological or endoscopic
diagnosis of cirrhosis (such as direct or indirect evidence
of portal hypertension).
For all patients, anthropomorphic data were collected
comprising gender, weight, height, body mass index
(BMI), and waist and thoracic circumferences. Serum
samples were obtained on the same day of liver biopsy
and subjected to routine laboratory biochemical tech-
niques for dosing of AST, alanine aminotransferase (ALT),
and platelet counts.
Histological evaluation
LB was performed percutaneously after local anesthe-
sia and mild sedation with a 14 gauge tru-cut needle. Liver
specimen fragments were considered acceptable at a
minimum of 15 and preferable 25 mm length. Histological
analysis was performed by a blinded senior institutional
liver pathologist after formalin fixation, paraffin embed-
ment, hematoxylin-eosin and Masson’s-Trichrome staining
for all samples and scored according to the METAVIR
fibrosis staging system (20). Fibrosis was either absent
(F0); confined to portal spaces without septa (F1);
extending beyond portal spaces with few portal-portal,
portal-center, center-center septa (F2); extending beyond
portal spaces with numerous septa (F3) or diffuse with
numerous septa and formation of regenerative nodules –
cirrhosis (F4). Significant fibrosis was defined as FX2 and
advanced fibrosis as FX3.
Noninvasive tests
TE measures were obtained with Fibroscan
s
, model
502 (Echosense) M probe, after 2-h fasting, on the right
lobe, through intercostal spaces with the patient in a
supine position. The unique blinded operator for TE
measurements was experienced in more than 100 prior
examinations, as recommended (16). LS values were
included in the analysis with at least 10 valid measures,
over 70% success rate and interquartile range (IQR) less
than 30% of the median value of LS measures. Significant
fibrosis was defined as LS above 7.1 kPa and advanced
fibrosis as LS above 9.5 kPa. Cirrhosis was diagnosed
when LS results were over 12.5 kPa. Discordance with LB
was defined as non-agreement on the basis of defined
parameters (significant fibrosis and advanced fibrosis).
APRI was calculated from components obtained on
the day of liver biopsy using the formula described in the
literature (AST in IU mL-1  upper limit of normality-1)/
platelet count (109/L). Significant fibrosis was defined as
highly unlikely when APRI was less than 0.5 and as highly
likely if APRI result was higher than 1.5. Advanced
fibrosis/cirrhosis was considered as highly improbable if
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APRI was lower than 1.0 and as highly probable if APRI
was higher than 2.0 (13). Noninvasive test performance
indicators were calculated using histological analysis as
the gold standard method.
Statistical analysis
The study population was analyzed with descriptive
statistical analysis using Epi-info version 3.5.4 (CDC,
USA) and OpenEpi version 3.03a (Emory, USA). Con-
tinuous variables were analyzed with Student’s t-test
or Mann-Whitney test, where appropriate. Categorical
variables were compared using the chi-square test.
Diagnostic performances for different tests were analyzed
separately and in combination according to sensitivity
(Se), specificity (Sp), negative predictive value (NPV) and
positive predictive values (PPV), positive likelihood ratio
(LR+), negative likelihood ratio (LR ), accuracy (Ac),
Cohen’s Kappa correlation value (k) and AUROC.
Test combinations were evaluated following a sequential
approach to potentially establish absence or presence of
significant (FX2) or advanced (FX3) fibrosis. Finally, using
an 85% accuracy threshold for predictability, the number of
liver biopsies potentially avoided were calculated. Baseline
continuous data are reported as medians, and categorical
variables are reported as frequencies or percentages.
Univariate analyses were performed using chi-square, Fisher,
and analysis of variation or Mann-Whitney, as appropriate.
Po0.05 was considered to be statistically significant.
Ethical considerations
Study design, protocols, patient enrolment, and data
collection and storage were in accordance with ethical
considerations supported by the updated 1975 Declara-
tion of Helsinki. Patients were included in the study after
written informed consent was obtained. The study was
reviewed and approved by the Ethics Committee for
Research of the School of Medical Sciences, State
University of Campinas (UNICAMP).
Results
During the study period, 198 patients were eligible
according to inclusion criteria. Of those, 12 (6,1%) were
excluded due to liver biopsy fragments with less than
15 mm and 4 (2,0%) were excluded after LS measure-
ments were considered invalid according with the described
criteria. A total of 182 patients were included in the final
analysis.
Demographic and clinical characteristics
Patient characteristics are presented in Table 1.
Median age was 55 years, 82 (70%) were Caucasians
and 73 (61%) were male. According to abdominal circum-
ferences, 16 (5.5%) patients were considered to be obese;
according to BMI, 18 (9.9%) patients were characterized
as obese.
Histological analysis
LB procedures did not result in any serious adverse
outcome. LB fragments median length was 18 mm and
was greater than 25 mm in 28% of samples. Mean number
of portal tracts was 9.8 (from 6 to 13). Histological
analysis results according to METAVIR scoring system
revealed that 15 (8.0%) patients were F0, 63 (35.0%)
were F1, 50 (28.0%) were F2, 45 (25.0%) were F3, and
9 (5.0%) were F4. Mild steatohepatitis was found in
11 (6.0%) patients, moderate steatohepatitis in 6 (3.3%)
and severe steatohepatitis in 4 (2.2%). Necroinflammatory
activity was absent (A0) in 21 patients (11.0%), mild (A1)
in 69 (38.0%), moderate (A2) in 73 (41%) and severe in
19 (10.0%).
Serum markers scoring system
APRI results were classifiable in 57% of cases, which
were deemed as highly unlikely for significant fibrosis in
87 (48%) of patients and as highly likely in 16 (9%).
Fibrosis level distribution among different APRI results are
Table 1. Baseline characteristics of the 182 patients included in the analysis.
Characteristic Value
Median age (years) 55 (21–74)
Sex (male) 111 (61.0%)
Caucasians 127 (70.0%)
BMI (kg/m2) 26.71 (19.11–42.39)
ALT (UI/L) 44 (18–117)
Mean abdominal perimeter (cm) 89 (68–132)
Mean thoracic perimeter (cm) 96 (72–118)
Obesity according to abdominal circumference 16 (5.5%)
Obesity according to BMI 18 (9.9%)
Data are reported as median and range, unless otherwise noted. BMI: body mass
index; ALT: alanine aminotransferase.
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shown in Figure 1. Specificity was 95% with LR+ of 5.18,
and AUROC of 0.71; other diagnostic performance indi-
cators are shown in Table 2.
APRI classification for advanced fibrosis/cirrhosis was
possible in 77% of patients (APRI o1.0 or 42.0). FX3
was found to be likely (APRI42.0) in 7 patients (4%) and
unlikely (APRIo1.0) in 134 (74%) patients, with 98%
specificity and 97% PPV with AUROC of 0.76.
Transient elastography
Mean time interval from LB to TE was 4.2 months
(range 0.5 to 7 months). In terms of quality control, IQR/
median presented high homogeneity with a median value
of 10% (range 7 to 16%) and 97% mean success rate.
LS values ranged from 2.6 to 42.8 kPa (median, 7.1 kPa).
TE showed significant fibrosis in 87 (48%) patients and
advanced fibrosis/cirrhosis in 57 (30%), as displayed
in Figure 2. For significant fibrosis, sensitivity was 68%
with PPV of 76% and NPV of 64%, and AUROC of 0.81.
For advanced fibrosis/cirrhosis specificity was 85% with
NPV of 89%, AUROC 0.87 and high correlation (k =0.57),
as shown in Table 3.
Combination of diagnostic tests
Correlation between APRI and TE for Fo2 was 100%
and, for Fo3, 98.4%. Combining both tests successfully
identified patients without significant fibrosis in 78% of
times (k=0.34, AUROC 0.86), and patients without
advanced liver fibrosis in 84% of cases (k=0.38, AUROC
0.90). AUROCs for individual tests as well as for
combinations are shown in Figure 3.
In order to stage patients using significant fibrosis as a
diagnostic target (FX2), combining APRI and TE could
have avoided LB in 54.5% of cases. For advanced
fibrosis/cirrhosis prediction, combination of TE and APRI
would have bypassed 76.3% of LB.
Figure 1. Box plot distribution of aspartate
aminotransferase to platelet index (APRI) results
according to METAVIR LB staging. First and third
quartiles are represented as top and bottom of the
boxes, and the error bars show minimum and
maximal values. The vertical length of the box
represents the interquartile range and the horizon-
tal line through the middle represent the median
value.
Table 2. Aspartate aminotransferase to platelet index (APRI) performance
indicators for significant (FX2) and advanced (FX3) fibrosis.
FX2 (95%CI) FX3 (95%CI)
Sensitivity 26% (11.81–48.79) 20% (5.668–50.98)
Specificity 95% (75.36–99.06) 98% (91.43–100)
PPV 85% (43.65–96.99) 97% (34.24–100)
NPV 56% (39.33–71.83) 86% (70.96–91.49)
Accuracy 68% (44.72–74.4) 72% (47.21–80.22)
LR+ 5.18 7.94
LR– 0.78 0.61
K 0.21 0.29
AUROC 0.71 0.76
CI: confidence interval; PPV: positive predictive value; NPV: negative predictive
value; LR+: positive likelihood ratio; LR–: negative likelihood ratio; K: Cohen’s
Kappa correlation value; AUROC: area under the receiver operating curve.
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Factors associated with test performances
Overall accuracy (AUROCs) was not significantly
affected by LB fragment length (420 vs o20 mm,
P=0.31), median ALT levels (450 vs o50 UI/mL, P=0.2)
or necroinflammatory activity grading in histological ana-
lysis (P=0.19). Low BMI (P=0.022) and smaller waist
circumferences (P=0.031) were associated with greater
AUROCs for TE (Table 4).
False negative TE results
For significant fibrosis, false negative TE results
comprised 32% of the study sample. On histological
analysis, 83% were classified as F2 and 7% were
found to be F4. Of note, 52% received non-classifiable
APRI results (40.5 and o1.5), 48% were also pre-
dicted to be Fo2 on APRI and none had APRI41.5.
On univariate analysis, lower necroinflammatory acti-
vity (Ao2 vs AX2, according to METAVIR system) was
associated with false negative TE results (OR=2.03,
95%CI=1.17–3.69). For advanced fibrosis, 26% of
patients falsely tested negative on TE, 82% of which
were F3 on LB. Of these, 79% had concordant APRI
results and the remainders were non-classifiable (none
had APRIo1.0).
False positive TE results
Among 28% of patients who tested positive on TE for
significant fibrosis and were found to be Fo2 on LB,
80% were F1 and 83% tested positive as well on APRI.
Liver fragments of less than 20 mm were associated with
false positive results on TE for significant fibrosis
(OR=2.58, 95%CI=1.79–7.22). For advanced fibrosis, of
the 15% false positives 78% were classified as F2 on
LB and 22% as F1. APRI results also were positive
for advanced fibrosis on 93% of these patients and,
on multivariate analysis, NASH diagnosed in LB was a
moderate predictor of false positive TE results (OR=1.98,
95%CI=1.17– 4.11).
Figure 2. Box plot distribution of Fibroscan results
according to METAVIR LB staging. First and third
quartiles are represented as top and bottom of the
boxes, and the error bars show minimum and
maximal values. The vertical length of the box
represents the interquartile range and the horizon-
tal line through the middle represent the median
value.
Table 3. Transient elastography performance indicators for significant (FX2) and
advanced (FX3) fibrosis.
FX2 (95%CI) FX3 (95%CI)
Sensitivity 68% (51.46–80.37) 74% (51.21–88.19)
Specificity 72% (54.28–85.30) 85% (72.31–92.59)
PPV 76% (58.98–87.17) 67% (45.37–82.81)
NPV 64% (46.62–77.81) 89% (76.50–95.16)
Accuracy 70% (57.78–79.45) 77% (61.11–83.01)
LR+ 2.45 4.95
LR– 0.45 0.31
K 0.39 0.57
AUROC 0.81 0.87
CI: confidence interval; PPV: positive predictive value; NPV: negative predictive
value; LR+: positive likelihood ratio; LR–: negative likelihood ratio; K: Cohen’s
Kappa correlation value; AUROC: area under the receiver operating curve.
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False negative APRI results
Fifty-four percent of patients that tested negative on
APRI for significant fibrosis were classified as FX2 on LB,
68% of which were F2 and 5% were F4. TE results were
also negative for significant fibrosis in 83% of cases.
Considering advanced fibrosis, 60% of negative APRI
results were found to be false negatives, 77% of which
were classified as F3 on LB. Of these, 94% also had
negative TE results. Age of less than 50 years was
associated with false negative APRI results for significant
fibrosis (OR=1.78, 95%CI=1.02–3.61).
False positive APRI results
Overall there were few instances of false positive
APRI results. For significant fibrosis, 5% of patients falsely
tested positive on APRI, all of whom were found to be F1
on LB but, on the other hand, also tested positive on TE.
Only 2% of patients tested positive on APRI for advanced
Table 4. Factors associated with diagnostic accuracy of transient elastography.
Univariate analysis
n (%) OR (95%CI) P
LB fragment length (425 mm) 51 (28) 1.28 (0.92–2.49) 0.31
Median AST (o50 UI/mL) 93 (51) 1.07 (0.96–2.12) 0.28
Median ALT (o50 UI/mL) 107 (59) 1.18 (0.91–4.33) 0.22
Female gender 71 (39) 1.04 (0.88–2.11) 0.41
BMI o30 (kg/m2) 129 (71) 1.19 (1.02–3.48) 0.02
Mean abdominal perimeter o105 (cm) 119 (65) 1.09 (1.01–2.12) 0.03
Necroinflammatory activity on LB o2 89 (49) 1.11 (0.84–2.83) 0.11
LB: liver biopsy; AST: aspartate aminotransferase; ALT: alanine aminotransferase; BMI: body mass index.
The Mann-Whitney test was used for statistical analysis.
Figure 3. Receiver-operating-characteristic (ROC) curves of noninvasive tests transient elastography (TE), aspartate aminotransferase
to platelet index (APRI) and a combination of both tests for significant (A) and advanced (B) fibrosis in chronic hepatitis C patients
compared to histological analysis through liver biopsy.
Braz J Med Biol Res | doi: 10.1590/1414-431X20165432
Fibroscan and APRI: performance and false positives/negatives 6/9
fibrosis and had LB results of Fo3 (66% were F2 and
33% were F1), all of whom tested positive on TE.
Discussion
We present a prospective cross-sectional study aimed
to evaluate the performance of two noninvasive LF staging
tests individually and combined, in an outpatient CHC
population in Brazil comprising 30% of patients with
advanced fibrosis. False positive and false negative
results and their correlated characteristics were also
evaluated.
Among different technologies for noninvasive LF
staging, LS determination using TE has been extensively
investigated in recent years (10,16,21) and therefore was
elected as one of the objects of our study. In the CHC
population, diagnostic performance indicators showed
good performance for ruling in and ruling out significant
or advanced fibrosis and cirrhosis. For significant fibrosis
(FX2), AUROC ranged from 0.85 to 0.91; for advanced
fibrosis (FX3), AUROC ranged from 0.87 to 0.92 and, for
cirrhosis, from 0.87 to 0.95. Our results are in con-
cordance with previous findings, showing moderate NPV
for FX2 (64%) and good NPV for FX3 (89%) with 0.81
and 0.87 AUROCs for significant and advanced fibrosis,
respectively. Differentiating specific levels of fibrosis
according to METAVIR scoring system, however, was
shown to be challenging for TE (22,23), especially in the
lower levels (F0 vs F1 and, to a lesser degree F1 vs F2).
Advanced fibrosis and cirrhosis prediction is well accom-
plished by TE, with best performances in ruling out
FX3 (24). Detection of significant fibrosis is somewhat
poorer than for cirrhosis or advanced fibrosis (AUROC
0.84 vs 0.94, respectively) (25). Diagnostic performance
for TE was significantly influenced by BMIo30kg/m2 and
lower abdominal perimeters. Study design precluded the
use of XL probes due to low reproducibility in previous
studies (26,27). M probe performance in obese and
overweight patients is indeed inferior, with more incon-
clusive and invalid test results.
APRI was the second diagnostic approach we studied
because it is a simple biomarker index and the most
widely available for predicting LF (13). It has been
extensively evaluated in CHC for diagnosis of significant
fibrosis and cirrhosis with different cut-off values (28).
For exclusion of significant fibrosis, results of less than 0.4
carry the greater sensitivity (88%), however, the 0.5 cut-off
for Fo2 is the most well studied (23 studies and
4,595 patients) with 74% sensitivity and 49% specificity.
APRI 41.5 is the optimal cut-off level for diagnosing
significant fibrosis (95% specificity). For advanced fibro-
sis, APRI o1.0 carries an 81% NPV (AUROC 0.80) and,
for APRI42.0, the specificity for FX3 is 93%. Comparing
APRI and LB for significant fibrosis and advanced fibrosis/
cirrhosis our results present slightly lower diagnostic
power (AUROC 0.78 and 0.82, respectively), although
APRI had very good correlation with TE results for both
Fo2 and Fo3 (83 and 94% of cases, respectively).
LB was used as the gold-standard test against which
others were compared. In recent years, attention has
been drawn to the fact that histological assessment of
liver specimens has its pitfalls and disadvantages. Sam-
pling error may be an issue considering the limited hepatic
tissue extension represented in a sample (1/50,000 of
actual mass) ranging from 45 to 55% according to
fragment length (3). Furthermore, as a highly operator-
dependent test, inter-observer variability has been shown
to reach 35% (3,29,30), with differences among reports of
up to 2 degrees of fibrosis. Intra-pathologist variability has
also been reported to be as high as 30%. Variability also
occurs when examining right and left lobes of the liver
separately with up to 33% discordance. Between two
fragments of at least 15 mm taken from the same puncture
site there was discordance of 1 or more fibrosis stages in
45% of cases (3,30,31).
Analyzing false negative TE results, significant fibrosis
prediction was moderately impaired by lower levels of
necroinflammatory activity on LB examination. Regarding
APRI, conversely, false negative results for significant
fibrosis were moderately influenced by age (less than
50 years). On the other hand, false positive on TE for
significant fibrosis was influenced by comparison to
LB results from fragments of less than 20 mm, which, as
previously described (6) carries the highest probability of
under staging in histological analysis. Also, presence of
NASH on LB was an independent predictor of false
positive TE for significant fibrosis, possibly acting as a
confounder both on LS parameters and associated inflam-
matory activity. Most importantly, both false negative
and false positive results of APRI and TE were highly
correlated, especially in lower levels of fibrosis, signaling a
possible important role of LB limitations as a determinant
of the somewhat low performance indicators of noninva-
sive tests.
Combining results of APRI and TE has not been
extensively explored in past studies. We found that
concordance between APRI and TE was 100 and 98.4%
for significant fibrosis and advanced fibrosis, respectively,
in spite of somewhat low individual diagnostic perfor-
mance indicators. In agreement with other authors
(20,32), limitations of histological analysis and possible
sampling errors intrinsic to LB were considered in our
study to be the main contributing factor for noninvasive
tests accuracy results. Furthermore, the association of TE
and APRI provides a reasonably cost-effective approach
to LF staging in resource-limited settings in comparison to
previously reported algorithms that combine LS with
patented scores such as Fibrotest.
In terms of study design, examination by a single liver
pathologist blind to the results of comparator tests repre-
sents a weakness in our study. Previous reports demon-
strate that experienced liver pathologists can produce LB
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examinations with over 20% of serious misclassifications
(2 degrees of fibrosis according to the METAVIR system)
(33). For that reason, many different groups (10–12,22)
employed double blind reading by different indepen-
dent pathologists, usually resorting to a third one for
discordant results. Analytical limitations notwithstanding,
single pathologist examination provides a more accurate
depiction of real life in clinical settings and decision-
making scenarios.
Another recognizable limitation of our population
sample is the low incidence of cirrhosis identified through
histological analysis. That in itself could lower accuracy
values for comparator tests. However, we have chosen to
elect the combined surrogate marker of advanced fibrosis,
comprising both METAVIR F3 and F4 stages, which has
been previously shown to correlate well with disease
progression among other clinical outcomes (34,35).
As previously observed, our results point to stronger
diagnostic performances in ruling out significant or
advanced fibrosis in the CHC population for the two
studied tests used individually or in combination. LB
avoidance needs not necessarily to be the only desired
outcome for noninvasive tests incorporation in clinical
practice. In fact, the use of noninvasive tests can also
play a pivotal role in providing pre-test probabilities for
critical and empowered interpretation of histological
analysis results in different clinical scenarios. Undeniably,
LB provides invaluable information for clinical decision-
making, such as necroinflammatory activity and steato-
hepatitis, which was present in 11% of our study
population and could otherwise have remained undiag-
nosed. Future research opportunities for further under-
standing performance indicators for noninvasive tests or
algorithms should consider correlation between different
modalities and the imperfect gold standard against which
they are challenged.
Nonetheless, specific METAVIR level staging remains
challenging across all noninvasive test modalities, with
very low accuracy and poor correlation among different
markers. Also, for most serum markers and for TE,
diagnostic performance is stronger in advanced levels of
fibrosis than for discriminating significant vs non-signifi-
cant fibrosis. However, considering the currently shifting
paradigm of CHC treatment from the ages of interferon-
based therapies with low success rate and unfavorable
safety profiles to highly efficacious and largely well tole-
rated directly acting antivirals, diagnosing specific levels of
fibrosis tends to be rendered less important in supporting
decision-making in clinical practice. In fact, deciding on
antiviral treatment indication will perhaps rely less on
determining patients who can await longer than others,
but rather on tailoring specific therapeutic regimens for
advanced levels of fibrosis or cirrhosis, as well as initiat-
ing recommended screening procedures, all of which
are suitable for noninvasive tests either isolated or in
combination.
Our results go beyond establishing diagnostic perfor-
mance through conventional indicators. We have analyzed
discordant results between noninvasive tests and LB and
determined associated predictive factors, as well as docu-
mented a strong correlation between serum biomarkers and
TE. Considering LB sample- and operator-related variability,
we suggest that accuracy-based performance standards for
noninvasive methods may be, in fact, conditioned by an
imperfect gold standard. Taking into account possible
interfering factors such as necroinflammatory activity or
NASH, TE and APRI, and especially their combined results
can potentially improve diagnostic capabilities.
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